Precision oncology startup @4baseCare secures Rs 128-Cr to expand AI-powered precision oncology platform Read more :- buff.ly/RkzwUsO #CancerDiagnostics #GenomicTesting #HealthcareTransformation #MedicalInnovation #PrecisionOncology

How do we decide which intermediate-risk prostate cancer patients need treatment intensification? Dr. Ruchika Talwar and Dr. Udit Singhal explore the clinical utility of the one biomarker test and its role in driving decisions around ADT and salvage therapy. While PSMA PET scans offer anatomical detail, genomic testing provides the biological insights necessary for truly personalized care. Watch the full episode here: backtable.com/shows/urology/… This podcast is supported by Veracyte. #URO301 #ProstateCancer #Biomarkers #GenomicTesting

భవిష్యత్తులో క్యాన్సర్ వచ్చే ప్రమాదాన్ని ఒక చిన్న పరీక్షతో ఇప్పుడే తెలుసుకోవచ్చా? Dr. Ch Mohana Vamsy #CancerAwareness #CancerPrevention #EarlyDetection #GeneticTesting #CancerScreening #PreventiveHealthcare #HealthAwareness #CancerRisk #GenomicTesting #HealthyLiving

Can a genomic test tip the scales between surveillance and treatment? Dr. Ruchika Talwar and Dr. Udit Singhal discuss how biomarker tests are shaping risk-adapted management, highlighting both the opportunities and the limitations of current molecular testing. The doctors also highlight practical considerations and discuss real-world cases. Watch the full episode here: backtable.com/shows/urology/… This podcast is supported by Veracyte. #URO301 #ProstateCancer #Biomarkers #GenomicTesting

🚨🎗️ ASCO26 | OPTIMA Trial Supports Chemotherapy De-escalation in Genomically Low-Risk HR /HER2− Early Breast Cancer Presenter/First Author: Robert C. Stein The phase III OPTIMA trial demonstrated that the 50-gene Prosigna® (PAM50) assay can identify a subgroup of clinically high-risk HR-positive/HER2-negative early breast cancer patients with minimal benefit from adjuvant chemotherapy. ✅ 4,153 patients enrolled ✅ HR /HER2− early breast cancer ✅ Up to 9 positive lymph nodes included ✅ Median follow-up: 4.0 years ✅ Primary endpoint: Invasive Breast Cancer-Free Survival (IBCFS) Among patients classified as low molecular risk (ROR ≤60): ✅ 5-year IBCFS: 93.6% with endocrine therapy alone vs 94.8% with chemotherapy endocrine therapy ✅ HR 1.06 (90% CI 0.80–1.40) ✅ Non-inferiority achieved (p=0.003) ✅ Absolute difference at 5 years: only 1.2% ✅ Similar outcomes across menopausal status, tumor size, grade, and nodal burden ✅ Consistent results observed even in patients with 4–9 positive lymph nodes and stage IIIA disease ✅ Premenopausal women receiving ovarian function suppression also maintained excellent outcomes The investigators concluded that Prosigna identified a population with little, if any, meaningful chemotherapy benefit. Based on the observed results, chemotherapy would prevent at most approximately 2 recurrences per 100 patients classified as low genomic risk. These findings further support the growing role of genomic profiling in refining adjuvant treatment decisions and safely reducing chemotherapy exposure in selected patients with clinically high-risk HR /HER2− early breast cancer. @OncoAlert #ASCO2026 #BreastCancer #HRPositiveBreastCancer #HER2Negative #EarlyBreastCancer #PrecisionOncology #GenomicTesting #PAM50 #Prosigna #AdjuvantTherapy #BreastOncology #CancerResearch #ASCO26 #OncologyAlert 🎗️

A major clinical trial suggests genomic testing can help many breast cancer patients skip chemotherapy. bit.ly/49xgt8B #BreastCancer #GenomicTesting #PrecisionMedicine

Can genomic data, not just PSA or MRI, guide your next prostate cancer treatment plan? Dr. Ruchika Talwar and Dr. Udit Singhal discuss biomarker tests and how they can supplement traditional testing strategies to reveal hidden molecular heterogeneity, inform prognosis, and predict treatment response in real-world practice. Watch the full episode here: backtable.com/shows/urology/… This podcast is supported by Veracyte. #URO301 #ProstateCancer #Biomarkers #GenomicTesting

#Genetictesting remains markedly underutilized across #urologiccancers in the United States, w/ only approximately 10% of eligible #patients undergoing testing within one year of diagnosis. Among 125,860 #patients w/ urologic cancers meeting criteria for #germlinetesting, % tested (100% eligible) #kidneycancer 9% #adrenalcancer 8% #uppertracturothelialcancer (UTUC) 16% #bladdercancer 8% #prostatecancer 10% ...higher proportion of Black men did not undergo #genetictesting for #prostatecancer, 14% vs 21% "the actual rates of #genetictesting may be lower than that observed in our study" c/w #PROCLAIM sciencedirect.com/science/ar… #DrNealShore et al. @EurUrolOncol '#Universal #Germline #GeneticTesting Standard of Care for #Patients W/ #ProstateCancer: The Time Is Now' #DrNealShore et al. @JCOOP_ASCO ascopubs.org/doi/10.1200/OP-… '#Universal #Germline & #Tumor #GenomicTesting Needed to Win the War Against #Cancer' ascopubs.org/doi/10.1200/JCO… @VivekSubbiah @Dr_R_Kurzrock #access #reducedisparities #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention @neerajaiims goldjournal.net/article/S009… #SriSaranManivasagam & #JayDRaman @urogoldjournal

When Sam Sufler lost his mom to glioblastoma, he decided to use his passion for running as a way to honor her. From the "Margarita Mile" to the LA Marathon, Sam has been involved with the Glioblastoma Foundation's mission to fund targeted treatments for glioblastoma. Now in his 8th year of volunteering with the Glioblastoma Foundation, Sam ran the LA Marathon in 2026 to help raise awareness and support genomic testing for every glioblastoma patient. Join us in thanking Sam for his awareness and fundraising efforts! 💜 instagram.com/p/DYfWiWnFD2d/… #GlioblastomaFoundation #communitystory #Glioblastoma #BrainCancerAwarenessMonth #TransformingGlioblastomaThearpy #GenomicTesting #BrainCancer #GlioblastomaAwareness

#GenomicTesting in #ProstateCancer: Management, applications, and treatment selection. @quimmateo @VHIO sits down with @neerajaiims @huntsmancancer outlining three everyday applications: using tumor and germline profiling to guide treatment selection (for example, PARP inhibitors in BRCA/HRR‑deficient disease), identifying patients and families with inherited cancer‑risk mutations, and deciphering mechanisms of resistance to current therapies so next‑line choices are smarter. #WatchNow > bit.ly/4toOuQP

BMT & Cellular Therapy Retreat ✔️ A day of collaboration and innovation—from genomic profiling to cell therapy advances. Grateful for our keynote speakers @GenomicTesting & @GlenBarberLab and this incredible community.

#GenomicTesting in #ProstateCancer: Management, applications, and treatment selection. @quimmateo @VHIO sits down with @neerajaiims @huntsmancancer outlining three everyday applications: using tumor and germline profiling to guide treatment selection (for example, PARP inhibitors in BRCA/HRR‑deficient disease), identifying patients and families with inherited cancer‑risk mutations, and deciphering mechanisms of resistance to current therapies so next‑line choices are smarter. #WatchNow > bit.ly/4toOuQP

35 runners. One powerful mission. 💜 Team Glioblastoma Foundation showed up strong at the LA Marathon, Charity Half, and 5K—running with purpose to bring genomic testing to every glioblastoma patient. Every mile mattered. Join us in celebrating this incredible team for making a difference that goes far beyond the finish line. #GlioblastomaFoundation #LAMarathon #Glioblastoma #GenomicTesting #TransformingGlioblastomaTherapy #Glioblastoma #BrainCancer

This week: @PhilFebboMD_CMO, Chief Scientific and Medical Officer at Veracyte, will be speaking at #PMWC26 on the future of whole-genome MRD and precision diagnostics. 📅 March 5, 2:30 PM PST Talk: "Improving Care with Every Test: Powering a Continuous Learning Cycle in Molecular Diagnostics" 💬 March 6, 1:30 PM PST Panel: "Diagnostics, Prognostics, and Patient Stratification" Learn more - pmwcintl.com/speaker/phil-fe… #TrueMRD #ctDNA #PrecisionMedicine #OncologyResearch #GenomicTesting #CancerDiagnostics #WholeGenomeSequencing

#GenomicTesting in #ProstateCancer: Management, applications, and treatment selection. @quimmateo @VHIO sits down with @neerajaiims @huntsmancancer outlining three everyday applications: using tumor and germline profiling to guide treatment selection (for example, PARP inhibitors in BRCA/HRR‑deficient disease), identifying patients and families with inherited cancer‑risk mutations, and deciphering mechanisms of resistance to current therapies so next‑line choices are smarter. #WatchNow > bit.ly/4toOuQP

🌍 We’re excited to support the evaluation of @GeneticAlliance’s iHope project with C-GUIDE, examining how #GenomicTesting informs diagnosis, care, and family wellbeing. Read more: shorturl.at/zJzkf

Mutations, fusions, protein expressions—knowing the full genomic landscape in NSCLC guides optimal therapy selection. Reflex testing ensures no “secrets” are missed. 🧬💉 Read more: hubs.ly/Q03_cd8c0 #OncologyResearch #GenomicTesting #NSCLC

#TeamVeracyte is excited to be at #SABCS25 and connect with oncologists, researchers, and colleagues advancing breast cancer care. 🤝 Stop by Booth #1432 to meet our team and discover how the #Prosigna Breast Cancer Assay is helping guide treatment decisions for women with early-stage HR breast cancer. We look forward to great conversations and exploring new research. When we get together, breast cancer diagnostics get ahead! #Veracyte #BreastCancer #ProsignaBreastCancerAssay #PrecisionMedicine #MedicalOncology #WomensHealth #BreastCancerResearch #GenomicTesting #PersonalizedMedicine #Oncology #Biotech #CancerCare

👀Want to find your Cross Breed Genomics Results? 👀 Check out this video 👇 on how to find your Cross Breed genomics results. youtu.be/RsmhpEGSyQM You mix. You breed. We test 📞 For more info on Genomic Testing call 03330 043 043 #GenomicTesting #CrossBreeding #NMR

📢Important Announcement📢 🙌The first Cross Breed Genomics Evaluations Are Coming!🙌 You mix. You breed. We test 📞 For more info on Genomic Testing call 03330 043 043 #GenomicTesting #CrossBreeding #CattleGenetics #LivestockInnovation #BreedBetter #NMR